Nitinotes Launches First Clinical Procedure in EASE™ IDE Trial at Orlando Health
Nitinotes Ltd., known for its innovative medical technologies, particularly the EndoZip™ Automated Suturing System for Endoscopic Sleeve Gastroplasty (ESG), achieved a significant milestone by performing the first study procedures at Orlando Health, a leading center for bariatric surgery. This event marks a key step in the company's pivotal EASE™ Investigational Device Exemption (IDE) trial aimed at evaluating the safety and effectiveness of the EndoZip™ system in treating obesity.
The procedures were executed by renowned bariatric surgeons, Dr. Andre F. Teixeira and Dr. Manoel Galvao Neto, both of whom are highly respected in the field of minimally invasive surgery and endoscopic treatments. With their extensive experience, they are set to enhance the study, which involves various centers that specialize in bariatric surgery and obesity management.
The EASE™ IDE trial is significant as it seeks to provide data that supports a future marketing submission to the U.S. Food and Drug Administration (FDA). This multicenter study aims to validate the advantages of using the EndoZip™ system for ESG, a minimally invasive procedure that displays promise for improving obesity treatment outcomes.
Lloyd Diamond, CEO of Nitinotes, expressed confidence in the partnership with Orlando Health, noting that the surgeons' expertise will greatly benefit the trial. "EndoZip™ was deliberately created to simplify and standardize the ESG procedure. Our goal is to facilitate application across a broad range of medical professionals, including those new to the endoscopic approach to obesity care."
Dr. Teixeira highlighted the evolution of obesity treatment, mentioning that the integration of minimally invasive endoscopic procedures into patient care is steadily growing. He remarked, "Techniques that help streamline complex procedures like ESG could revolutionize how they are adopted, ensuring consistency and reliability in treatment. We eagerly anticipate evaluating the EndoZip™ system throughout the course of this trial."
Notably, the EndoZip™ system is already CE marked in Europe, permitting its commercial use across the EU and other regions that recognize CE accreditation; however, in the United States, it is strictly limited to investigational use pending FDA clearance.
The EASE™ Clinical Trial is carefully designed, structured as a randomized, controlled, two-arm, blinded study that focuses on verifying the comprehensive safety and effectiveness of the EndoZip™ system specifically for patients battling obesity. The findings will provide valuable insights and contribute to shifting the landscape of obesity care and treatment.
Nitinotes continues to position itself at the forefront of medical advancements with the EndoZip™ platform, which aims not just to improve techniques but also to enhance the overall standard of endoluminal suturing for a variety of conditions. As more centers like Orlando Health join this pivotal trial, the future of endoscopic obesity treatments looks promising, potentially leading to improved outcomes for countless patients.
For those interested in more information about Nitinotes and the EndoZip™ system, additional details can be found on their official website. As clinical trials progress, the medical community and patients alike will be keenly observing the outcomes of this innovative approach to obesity management.
The procedures were executed by renowned bariatric surgeons, Dr. Andre F. Teixeira and Dr. Manoel Galvao Neto, both of whom are highly respected in the field of minimally invasive surgery and endoscopic treatments. With their extensive experience, they are set to enhance the study, which involves various centers that specialize in bariatric surgery and obesity management.
The EASE™ IDE trial is significant as it seeks to provide data that supports a future marketing submission to the U.S. Food and Drug Administration (FDA). This multicenter study aims to validate the advantages of using the EndoZip™ system for ESG, a minimally invasive procedure that displays promise for improving obesity treatment outcomes.
Lloyd Diamond, CEO of Nitinotes, expressed confidence in the partnership with Orlando Health, noting that the surgeons' expertise will greatly benefit the trial. "EndoZip™ was deliberately created to simplify and standardize the ESG procedure. Our goal is to facilitate application across a broad range of medical professionals, including those new to the endoscopic approach to obesity care."
Dr. Teixeira highlighted the evolution of obesity treatment, mentioning that the integration of minimally invasive endoscopic procedures into patient care is steadily growing. He remarked, "Techniques that help streamline complex procedures like ESG could revolutionize how they are adopted, ensuring consistency and reliability in treatment. We eagerly anticipate evaluating the EndoZip™ system throughout the course of this trial."
Notably, the EndoZip™ system is already CE marked in Europe, permitting its commercial use across the EU and other regions that recognize CE accreditation; however, in the United States, it is strictly limited to investigational use pending FDA clearance.
The EASE™ Clinical Trial is carefully designed, structured as a randomized, controlled, two-arm, blinded study that focuses on verifying the comprehensive safety and effectiveness of the EndoZip™ system specifically for patients battling obesity. The findings will provide valuable insights and contribute to shifting the landscape of obesity care and treatment.
Nitinotes continues to position itself at the forefront of medical advancements with the EndoZip™ platform, which aims not just to improve techniques but also to enhance the overall standard of endoluminal suturing for a variety of conditions. As more centers like Orlando Health join this pivotal trial, the future of endoscopic obesity treatments looks promising, potentially leading to improved outcomes for countless patients.
For those interested in more information about Nitinotes and the EndoZip™ system, additional details can be found on their official website. As clinical trials progress, the medical community and patients alike will be keenly observing the outcomes of this innovative approach to obesity management.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.